Seth Wander, MD, PhD, Mass General, and Maxwell Lloyd, MD, Beth Israel Deaconess Medical Center, discuss the growing use of real-world data to study treatment patterns, drug sequencing, and biomarker associations in metastatic breast cancer.
Drawing on recent claims database analyses and observational research, this session examines how these data are used to evaluate clinical practice, generate hypotheses, and identify evidence gaps—while also exploring the important limitations and challenges of interpreting real-world evidence.